A Phase 1 Study of KHK4083: A Single‐Blind, Randomized, Placebo‐Controlled Single‐Ascending‐Dose Study in Healthy Adults and an Open‐Label Multiple‐Dose Study in Patients With Ulcerative Colitis-Reference-Cited by-同舟云学术

A Phase 1 Study of KHK4083: A Single‐Blind, Randomized, Placebo‐Controlled Single‐Ascending‐Dose Study in Healthy Adults and an Open‐Label Multiple‐Dose Study in Patients With Ulcerative Colitis

Published:2021-01-29 Issue:8 Volume:10 Page:870-883
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Furihata Kenichi¹,Ishiguro Yoh²,Yoshimura Naoki³,Ito Hiroaki⁴,Katsushima Shinji⁵,Kaneko Etsuji⁶,Shimabe Munetake⁶,Mukai Mayumi⁶,Watanabe Risa⁶,Morishige Takuya⁶

Affiliation:

1. P‐One Clinic, Keikokai Medical Corporation Tokyo Japan

2. Department of Clinical Research National Hirosaki Hospital, National Hospital Organization Aomori Japan

3. Department of Medicine Division of Gastroenterology Tokyo Yamate Medical Center Tokyo Japan

4. Kinshukai Infusion Clinic Osaka Japan

5. Department of Gastroenterology Kyoto Medical Center, National Hospital Organization Kyoto Japan

6. Kyowa Kirin Co., Ltd Tokyo Japan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.918

Reference30 articles.

1. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis

2. The role of TNF superfamily members in T-cell function and diseases

3. Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

4. Advances in the development of cancer immunotherapies

5. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Caecum OX40+CD4 T-cell subset associates with mucosal damage and key markers of disease in treated HIV-infection;Journal of Microbiology, Immunology and Infection;2023-12

2. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future;Frontiers in Immunology;2023-04-06

3. Landscape of new drugs and targets in inflammatory bowel disease;United European Gastroenterology Journal;2022-09-16

4. Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies;Frontiers in Immunology;2022-06-30